Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

GBT Appoints Wendy L. Yarno to Board of Directors

bluebird bio to Present at Investor Conferences in January

TARIS Biomedical® Announces $25M Series B Financing

TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration